CanBas and Takeda, along with Takeda Oncology, have initiated Phase II clinical trials for CBP501, a treatment for patients affected with non-small cell lung cancer (NSCLC).
The Phase I study indicated that CBP501 may enhance anti-cancer cytotoxic activity, when combined with selected chemotherapeutic drugs.
The partnership to enter into trials for CBP501 was signed by CanBas and Takeda in March 2007. The collaboration is intended for the development of investigational compounds to treat patients with cancer (including CBP501 and its backup compounds discovered by CanBas).
As per the agreement Japan's Takeda has been granted worldwide exclusive rights for development, manufacturing and marketing. Both companies will be jointly responsible for development and promotion in the US.
CanBas president and CEO Takumi Kawabe said that the company was excited to see CBP501 moving to Phase II trials in NSCLC.
"This is the second Phase II trial for CBP501, and we look forward to advancing both indications toward an eventual marketing authorisation," Kawabe said.